Kisspeptin Dosage: 45 Studies, 26 Completed, 0 Approvals
Kisspeptin has around 45 registered studies and roughly 26 completed, mostly academic. What those counts change about a dosage figure, and what they do not.
MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Kisspeptin dosage is one of the few questions on this site where published human numbers exist to divide into. Most pages here reconstruct a figure from rodent work and a conversion that does not hold; this one does not have to.
Three counts frame it: 45 registered studies, about 26 completed, and 0 approved products. The third count is the one that decides what a chart can claim.
The counts, and where they came from
ClinicalTrials.gov returns roughly 45 studies under the name. The phase split is unusual for anything covered here.
| Phase | Studies |
|---|---|
| Phase 3 | 4 |
| Phase 2 | 9 |
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Not applicable | 20 |
About 26 are recorded as completed. The sponsors are academic: an individual investigator and Massachusetts General Hospital hold the largest blocks, with Imperial College London and university hospitals elsewhere adding more. PubMed carries several thousand records on the peptide and its receptor.
What that does to the arithmetic on this page
Every reconstitution calculation here is the same: labelled mass divided by diluent volume gives a concentration, and volume drawn times concentration gives what is in the syringe. The arithmetic is exact. The recurring problem across this site is that there is no established quantity for it to land on.
Kisspeptin partly solves that problem. Published human studies used specific amounts and measured the hormonal result, so a target figure exists in the literature rather than only in a rodent paper requiring a species conversion.
It does not solve the other half. Those amounts were selected to produce a measurable response in a defined patient group under supervision, with assays reading the outcome. A figure carried out of that setting is no longer the figure the study established, even though the arithmetic treats it identically.
The count that limits everything else
No regulator has approved kisspeptin as a marketed medicine, so the count of authorised doses is zero.
That is the distinction a kisspeptin dosage chart has to carry. It can restate quantities used in published trials, which is a genuinely better source than most charts in this category have. It cannot present any of them as an authorised dose, because no authority set one and nobody is accountable for the number.
There is also the input problem that applies to every research-chemical vial on this site: the labelled mass at the top of the calculation is a seller's claim rather than a verified assay, and the arithmetic inherits that error exactly.
Frequently Asked Questions
How many human studies of kisspeptin are registered?expand_more
Around 45 on ClinicalTrials.gov, of which roughly 26 are recorded as completed, including four in Phase 3.
Is there an authorised dose?expand_more
No. No regulator has approved the compound as a marketed medicine, so no label exists and no quantity has been authorised.
Are the published quantities usable as a target?expand_more
They are a real starting point in a way rodent figures are not, but they came from defined patient groups with measured hormonal endpoints under supervision. Outside that setting they are an extrapolation.
What were the trials studying?expand_more
The reproductive axis: puberty disorders, hypogonadotropic hypogonadism, fertility, and use as a trigger in assisted reproduction.
Does the arithmetic on this site apply?expand_more
Yes, and it is exact given an accurate label. The uncertainty sits in the labelled mass on a research vial and in whether the target figure applies outside its study population.
References & Citations
- [1]
ClinicalTrials.gov. Studies registered under the term kisspeptin: approximately 45 records, roughly 26 completed, four in Phase 3; lead sponsors predominantly academic.View source →